UPDATE 3-Merck predicts lung cancer dominance for Keytruda immunotherapy
October 25, 2016 at 12:11 PM EDT
NEW YORK, Oct 25 - Merck & Co on Tuesday declared its intention to dominate the large and lucrative lung cancer market, bolstered by a significant expansion of approved U.S. uses for its drug that helps the immune system attack tumors.
